keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy metastatic breast cancer

keyword
https://www.readbyqxmd.com/read/28646810/synergistic-anti-breast-cancer-effects-of-combined-treatment-with-oleuropein-and-doxorubicin-in-vivo
#1
Maha H Elamin, Abdelsalam B Elmahi, Maha H Daghestani, Ebtesam M Al-Olayan, Reem A Al-Ajmi, Afrah F Alkhuriji, Sherifa S Hamed, Manal F Elkhadragy
Context • Breast cancer is a leading cause of cancer fatalities among women worldwide. Of the more than 80% of patients who receive adjuvant chemotherapy, approximately 40% relapse. The majority of these patients die of disseminated metastatic disease, which emphasizes the need for new therapeutic strategies Objective • The study intended to investigate the anticancer effects of oleuropein (OL) and doxorubicin (DOX) individually and in combination on breast tumor xenografts and also to evaluate the molecular pathways involved...
June 23, 2017: Alternative Therapies in Health and Medicine
https://www.readbyqxmd.com/read/28646261/hepatic-arterial-infusion-chemotherapy-for-extensive-liver-metastases-of-breast-cancer-efficacy-safety-and-prognostic-parameters
#2
Mitra Tewes, Michael Wilhelm Peis, Simon Bogner, Jens M Theysohn, Marcus Paul Reinboldt, Martin Schuler, Anja Welt
PURPOSE: Hepatic arterial infusion chemotherapy (HAIC) is an option for patients with liver-predominant metastatic breast cancer (LMBC), when no further systemic treatment is available. But systematic reports are limited. Here we conducted a retrospective analysis of LMBC patients treated at an expert center. METHODS: Individual patient data were retrieved from the clinical data base of the West German Cancer Center. Primary endpoints included hepatic response (RECIST), progression-free survival (PFS), overall survival (OS), and toxicity...
June 23, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28643430/platinum-containing-regimens-for-metastatic-breast-cancer
#3
REVIEW
Sam J Egger, Melina L Willson, Jenna Morgan, Harriet S Walker, Sue Carrick, Davina Ghersi, Nicholas Wilcken
BACKGROUND: Studies have reported high tumour response rates for platinum-containing regimens in the treatment of women with metastatic breast cancer. Most of these studies were conducted prior to the 'intrinsic subtype' era, and did not specifically focus on metastatic triple-negative breast cancers (mTNBCs). OBJECTIVES: To identify and review the evidence from randomised trials comparing platinum-containing chemotherapy regimens with regimens not containing platinum in the management of women with metastatic breast cancer...
June 23, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28639285/porphyrin-modified-trastuzumab-improves-efficacy-of-her2-targeted-photodynamic-therapy-of-gastric-cancer
#4
Barbara Korsak, Gabriela M Almeida, Sara Rocha, Carla Pereira, Nuno Mendes, Hugo Osório, Patrícia M R Pereira, João M M Rodrigues, Rudolf J Schneider, Bruno Sarmento, João P C Tomé, Carla Oliveira
Gastric cancer (GC) is the 3(rd) deadliest cancer worldwide, due to limited treatment options and late diagnosis. Human epidermal growth factor receptor-2 (HER2) is overexpressed in ∼20% of GC cases and anti-HER2 antibody trastuzumab in combination with conventional chemotherapy, is recognized as standard therapy for HER2-positive metastatic GC. This strategy improves GC patients' survival by 2-3 months, however its optimal results in breast cancer indicate that GC survival may be improved. A new photoimmunoconjugate was developed by conjugating a porphyrin with trastuzumab (Trast:Porph) for targeted photodynamic therapy in HER2-positive GC...
June 22, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28636984/whether-low-dose-metronomic-oral-cyclophosphamide-improves-the-response-to-docetaxel-in-first-line-treatment-of-non-triple-negative-metastatic-breast-cancer
#5
Jian Zhang, Leiping Wang, Zhonghua Wang, Biyun Wang, Jun Cao, Fangfang Lv, Sheng Zhang, Zhimin Shao, Xichun Hu
Oral metronomic chemotherapy may target tumor cells indirectly via antiangiogenic activity, restoration of anticancer immune response, or induction of tumor dormancy. We initiated the single-center, randomized, open-label, phase II study to determine whether the addition of metronomic cyclophosphamide to docetaxel (T) (w/o trastuzumab) improves overall response rate (ORR) as first-line treatment among patients with non-triple-negative metastatic breast cancer (MBC). Eligible patients with previously untreated non-triple-negative MBC were randomly assigned (1:1) to receive 3-weekly cycles of Metro-TC (T 75mg/m2, d1 plus oral cyclophosphamide 50 mg daily) or T alone...
June 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28626727/mast-cell-infiltration-in-human-brain-metastases-modulates-the-microenvironment-and-contributes-to-the-metastatic-potential
#6
Ananya Roy, Sylwia Libard, Holger Weishaupt, Ida Gustavsson, Lene Uhrbom, Göran Hesselager, Fredrik J Swartling, Fredrik Pontén, Irina Alafuzoff, Elena Tchougounova
Metastatic brain tumors continue to be a clinical problem, despite new therapeutic advances in cancer treatment. Brain metastases (BMs) are among the most common mass lesions in the brain that are resistant to chemotherapies, have a very poor prognosis, and currently lack any efficient diagnostic tests. Predictions estimate that about 40% of lung and breast cancer patients will develop BM. Despite this, very little is known about the immunological and genetic aberrations that drive tumorigenesis in BM. In this study, we demonstrate the infiltration of mast cells (MCs) in a large cohort of human BM samples with different tissues of origin for primary cancer...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28625341/efficacy-and-toxicity-of-metronomic-chemotherapy-in-metastatic-breast-cancer-egyptian-experience
#7
Marwa Mahmoud Hussein, Rabab Mohamed Gaafar, Ahmed Mostafa Abdel-Warith, Wafaa Abdallah Ahmed, Nasr Mohamed Ali Allahloubi, Salem Eid Salem, Ibrahem Mohamed Abdel-Salam
BACKGROUND: Metronomic chemotherapy (MC) has shown efficacy in patients with metastatic breast cancer (MBC). We therefore tested the efficacy and toxicity of MC in pretreated MBC. PATIENTS AND METHODS: This prospective phase II study included 50 patients with heavily pretreated MBC who received MC in the form of continuous oral cyclophosphamide 50 mg/day and oral methotrexate 2.5 mg twice per day on days 1 and 2 every week. The primary end point was progression-free survival (PFS), whereas the secondary end points were response rate, overall survival (OS), and safety...
May 8, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28622765/unusual-primary-breast-cancer-malignant-peripheral-nerve-sheath-tumor-a-case-report-and-review-of-the-literature
#8
Md Shuayb, Rabeya Begum
BACKGROUND: Sarcomas are a rare type of breast malignancies and malignant peripheral nerve sheath tumors of the breast are even rarer. There are no specific clinical and radiological features for the diagnosis of this tumor and histological features are also reported to be nonspecific. Therefore, immunohistochemistry is required for its diagnosis. A definitive treatment protocol is unavailable because of its rarity. CASE PRESENTATION: We report a case of a sporadic form of breast malignant peripheral nerve sheath tumor found in a 16-year-old Asian Bangladeshi girl...
June 17, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28621227/expression-of-epithelial-mesenchymal-transition-driver-brachyury-and-status-of-tumor-infiltrating-cd8-and-foxp3-lymphocytes-in-predicting-treatment-responses-to-neoadjuvant-chemotherapy-of-breast-cancer
#9
Kwan Ho Lee, Eun Young Kim, Yong Lai Park, Sung-Im Do, Seoung Wan Chae, Chan Heun Park
Brachyury has been characterized as a driver of epithelial-mesenchymal transition process which is regarded as an important mechanism of cancer cell invasion and metastatic progression. The status of tumor-infiltrating lymphocytes has been proposed to predict response to neoadjuvant chemotherapy in breast cancer. We investigated the clinical significance and value of tumor-infiltrating lymphocytes and brachyury as biomarkers to predict treatment responses to neoadjuvant chemotherapy in breast cancer. We also examined the correlation of the Neo-Bioscore with tumor-infiltrating lymphocytes and brachyury to indirectly predict long-term outcome...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28620884/kinetic-pharmacodynamic-model-of-chemotherapy-induced-peripheral-neuropathy-in-patients-with-metastatic-breast-cancer-treated-with-paclitaxel-nab-paclitaxel-or-ixabepilone-calgb-40502-alliance
#10
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, Kehua Wu, William T Barry, Clifford Hudis, Eric P Winer, Alan P Lyss, Deborah L Toppmeyer, Alvaro Moreno-Aspitia, Thomas E Lad, Mario Valasco, Beth Overmoyer, Hope Rugo, Mark J Ratain, Jogarao V Gobburu
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity caused by several chemotherapeutic agents. Currently, CIPN is managed by empirical dose modifications at the discretion of the treating physician. The goal of this research is to quantitate the dose-CIPN relationship to inform the optimal strategies for dose modification. Data were obtained from the Cancer and Leukemia Group B (CALGB) 40502 trial, a randomized phase III trial of paclitaxel vs. nab-paclitaxel vs. ixabepilone as first-line chemotherapy for locally recurrent or metastatic breast cancer...
June 15, 2017: AAPS Journal
https://www.readbyqxmd.com/read/28616827/trastuzumab-and-survival-of-patients-with-metastatic-breast-cancer
#11
Karin Kast, Olaf Schoffer, Theresa Link, Almuth Forberger, Andrea Petzold, Antje Niedostatek, Carmen Werner, Stefanie J Klug, Andreas Werner, Axel Gatzweiler, Barbara Richter, Gustavo Baretton, Pauline Wimberger
INTRODUCTION: Prognosis of Her2-positive breast cancer has changed since the introduction of trastuzumab for treatment in metastatic and early breast cancer. It was described to be even better compared to prognosis of Her2-negative metastatic breast cancer. The purpose of this study was to evaluate the effect of trastuzumab in our cohort. Besides the effect of adjuvant pretreatment with trastuzumab on survival of patients with metastatic Her2-positive breast cancer was analyzed. METHODS: All patients with primary breast cancer of the Regional Breast Cancer Center Dresden diagnosed during the years 2001-2013 were analyzed for treatment with or without trastuzumab in the adjuvant and in the metastatic treatment setting using Kaplan-Meier survival estimation and Cox regression...
June 14, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28616768/antitumor-activity-and-safety-profile-of-weekly-carboplatin-plus-paclitaxel-in-metastatic-breast-cancer-a-ten-year-monocentric-retrospective-study
#12
Claudio Vernieri, Monica Milano, Alessia Mennitto, Claudia Maggi, Benvenuto Ferrari, Lucia Rinaldi, Roberta Mennitto, Claudia Stefanetti, Barbara Re, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Filippo de Braud
BACKGROUND: Taxanes are a mainstay in the treatment of metastatic breast cancer (mBC). Combination chemotherapy, including platinum-taxens doublets, can improve tumor responses and progression-free survival (PFS), but is associated with more toxicities and an uncertain benefit in terms of overall survival (OS). METHODS: We performed a retrospective study on 274 consecutive patients with mBC treated at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, during the decade 2007-2016 with the combination of carboplatin AUC 2 plus paclitaxel 80 mg/m(2), both given on days 1 and 8 in every 21-day cycle...
June 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28614979/docetaxel-induced-cardiac-respiratory-arrest-in-a-patient-with-chronic-atrial-fibrillation
#13
Mostaqul Huq, Tracie M Balvanz, Scott Mambourg
Docetaxel has been approved by the Food and Drug Administration for the treatment of many cancer types, including breast cancer, head and neck cancer, lung cancer, and prostate cancer. Many severe to life-threatening side effects (Grades 3-5) of docetaxel have been reported in clinical trials, case reports, and Food and Drug Administration Adverse Events Reporting System. These include anaphylactic reactions, febrile neutropenia, fluid retention, acute respiratory distress, pleural effusion, pneumonia, and peripheral neuropathy...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28612225/prolonged-survival-in-patients-with-breast-cancer-and-a-history-of-brain-metastases-results-of-a-preplanned-subgroup-analysis-from-the-randomized-phase-iii-beacon-trial
#14
Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, Seock-Ah Im, Patricia Gómez-Pardo, Lee S Schwartzberg, Veronique Diéras, Denise A Yardley, David A Potter, Audrey Mailliez, Alvaro Moreno-Aspitia, Jin-Seok Ahn, Carol Zhao, Ute Hoch, Mary Tagliaferri, Alison L Hannah, Joyce O'Shaughnessy
PURPOSE: Conventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. METHODS: The phase 3 BEACON trial enrolled 852 women with heavily pretreated locally recurrent or metastatic breast cancer between 2011 and 2013...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28611109/an-in-vivo-functional-screen-identifies-jnk-signaling-as-a-modulator-of-chemotherapeutic-response-in-breast-cancer
#15
Matthew Ashenden, Antoinette van Weverwijk, Nirupa Murugaesu, Antony Fearns, James Campbell, Qiong Gao, Marjan Iravani, Clare M Isacke
Chemotherapy remains the mainstay of treatment for advanced breast cancer, however, resistance is an inevitable event for the majority of patients with metastatic disease. Moreover, there is little information available to guide stratification of first line chemotherapy, crucial given the common development of multidrug resistance. Here we describe an in vivo screen to interrogate the response to anthracycline-based chemotherapy in a syngeneic metastatic breast cancer model, and identify JNK signaling as a key modulator of chemotherapy response...
June 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28608931/the-association-between-germline-brca2-variants-and-sensitivity-to-platinum-based-chemotherapy-among-men-with-metastatic-prostate-cancer
#16
Mark M Pomerantz, Sandor Spisák, Li Jia, Angel M Cronin, Istvan Csabai, Elisa Ledet, A Oliver Sartor, Irene Rainville, Edward P O'Connor, Zachary T Herbert, Zoltan Szállási, William K Oh, Philip W Kantoff, Judy E Garber, Deborah Schrag, Adam S Kibel, Matthew L Freedman
BACKGROUND: Breast cancer 2 (BRCA2)-associated breast and ovarian cancers are sensitive to platinum-based chemotherapy. It is unknown whether BRCA2-associated prostate cancer responds favorably to such treatment. METHODS: A retrospective analysis of a single-institution cohort of men with castration-resistant, metastatic prostate cancer was performed to determine the association between carrier status of pathogenic BRCA2 germline variants and prostate-specific antigen response to carboplatin-based chemotherapy...
June 13, 2017: Cancer
https://www.readbyqxmd.com/read/28605730/gemcitabine-and-vinorelbine-combination-chemotherapy-in-taxane-pretreated-patients-with-metastatic-breast-cancer-a-phase-ii-study-of-the-kinki-multidisciplinary-breast-oncology-group-kmbog-1015
#17
Jun Yamamura, Norikazu Masuda, Daigo Yamamoto, Shigeru Tsuyuki, Masahide Yamaguchi, Satoru Tanaka, Junji Tsurutani, Shinya Tokunaga, Katsuhide Yoshidome, Makiko Mizutani, Toyokazu Aono, Asako Ooe, Hirokazu Tanino, Nobuki Matsunami, Hiroyuki Yasojima, Takahiro Nakayama, Yukihiro Nishida
BACKGROUND: This phase II study was conducted to evaluate the efficacy and safety of the chemotherapy combination of gemcitabine and vinorelbine in taxane-pretreated Japanese metastatic breast cancer patients. METHODS: In this multicenter, phase II, single-arm study, patients with recurrent or metastatic HER2-negative breast cancer were administered gemcitabine (1,200 mg/m2) and vinorelbine (25 mg/m2) intravenously on days 1 and 8 every 3 weeks. The primary endpoint was the objective response rate, and other endpoints included progression-free survival, overall survival, and safety...
June 13, 2017: Chemotherapy
https://www.readbyqxmd.com/read/28604109/viral-gene-therapy-for-breast-cancer-progress-and-challenges
#18
Antonela S Asad, Mariela A Moreno Ayala, M Florencia Gottardo, Camila Zuccato, Alejandro Javier Nicola Candia, Flavia A Zanetti, Adriana Seilicovich, Marianela Candolfi
Breast cancer is the most common cancer in women all over the world. Furthermore, up to one third of breast tumors develop metastases that are resistant to standard therapies. Gene therapeutic strategies have been developed in order to specifically target cancer cells either directly or through the stimulation of antitumor immunity. Areas covered: This review describes the therapeutic strategies that are currently under development to treat this disease using engineered viral vectors including: adenovirus, adeno-associated virus, lentivirus, poxvirus, reovirus, baculovirus, herpesvirus and oncolytic viruses...
June 12, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28601382/long-term-follow-up-of-node-negative-breast-cancer-patients-evaluated-via-sentinel-node-biopsy-after-neoadjuvant-chemotherapy
#19
Hiroko Nogi, Ken Uchida, Rei Mimoto, Makiko Kamio, Hisashi Shioya, Yasuo Toriumi, Masafumii Suzuki, Eijiro Nagasaki, Tadashi Kobayashi, Hiroshi Takeyama
BACKGROUND: Sentinel node biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. However, its use after neoadjuvant chemotherapy (NAC) is controversial. We retrospectively assessed the usefulness of SNB after NAC by comparing axillary recurrence rates and other parameters in patients with clinically node-negative breast cancer who underwent SNB after NAC or without NAC. PATIENTS AND METHODS: At our hospital, 1179 patients with clinically node-negative breast cancer underwent SNB from April 2007 to December 2013...
May 8, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28597105/role-of-aspirin-in-breast-cancer-survival
#20
REVIEW
Wendy Y Chen, Michelle D Holmes
Chemotherapy and hormonal therapy have significantly decreased breast cancer mortality, although with considerable side effects and financial costs. In the USA, over three million women are living after a breast cancer diagnosis and are eager for new treatments that are low in toxicity and cost. Multiple observational studies have reported improved breast cancer survival with regular aspirin use. Furthermore, pooled data from five large randomized trials of aspirin for cardiovascular disease showed that subjects on aspirin had decreased risk of cancer mortality and decreased risk of metastatic cancer...
July 2017: Current Oncology Reports
keyword
keyword
117545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"